REDX.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 00:28):

Stats
今日成交量	20.48M
平均成交量	838 041
市值	58.35M
EPS	£-0.0370 ( Q4 \| 2023-09-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.500 (Sector) 0 (Industry) 0
ATR14	£2.03 (13.52%)

AMYT.L -11.73%

APH.L 0.28%

AVCT.L -1.49%

AZN.L -0.44%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.40%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 1.10%

GNS.L 1.45%

GSK.L -0.53%

HCM.L -0.36%

HEMO.L -2.66%

HIK.L -0.53%

IMM.L -1.15%

INDV.L 0.24%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 0.98%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 8.67%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

音量相关性

長: -0.34 (neutral)

短: 0.93 (very strong)

Signal:(57.69) Expect same movement, but be aware

Redx Pharma PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Redx Pharma PLC 相关性 - 货币/商品

0.64
( weak )

0.50
( neutral )

0.66
( moderate )

-0.01
( neutral )

-0.63
( weak negative )

0.11
( neutral )

Redx Pharma PLC 财务报表

Annual	2023
营收:	£4.20M
毛利润:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2023
营收:	£4.20M
毛利润:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2022
营收:	£18.69M
毛利润:	£18.69M (100.00 %)
EPS:	£-0.0612

FY	2021
营收:	£10.04M
毛利润:	£0.00 (0.00 %)
EPS:	£-0.127

Financial Reports:

No articles found.

Redx Pharma PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.